Analysts expect that Intersect ENT (NASDAQ:XENT) will post ($0.17) earnings per share (EPS) for the current quarter, Zacks reports. Seven analysts have provided estimates for Intersect ENT’s earnings. The lowest EPS estimate is ($0.21) and the highest is ($0.11). Intersect ENT posted earnings of ($0.08) per share in the same quarter last year, which suggests a negative year-over-year growth rate of 112.5%. The business is expected to report its next earnings report on Tuesday, August 7th.
On average, analysts expect that Intersect ENT will report full-year earnings of ($0.64) per share for the current financial year, with EPS estimates ranging from ($0.75) to ($0.53). For the next financial year, analysts forecast that the business will post earnings of ($0.21) per share, with EPS estimates ranging from ($0.45) to $0.05. Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover Intersect ENT.
Intersect ENT (NASDAQ:XENT) last issued its quarterly earnings results on Tuesday, May 1st. The medical equipment provider reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.02. The business had revenue of $24.70 million during the quarter, compared to analyst estimates of $23.66 million. Intersect ENT had a negative net margin of 15.73% and a negative return on equity of 13.67%. Intersect ENT’s revenue for the quarter was up 20.5% compared to the same quarter last year. During the same quarter last year, the business posted ($0.23) earnings per share.
A number of analysts recently weighed in on XENT shares. Zacks Investment Research reissued a “hold” rating on shares of Intersect ENT in a report on Saturday, April 7th. BidaskClub raised shares of Intersect ENT from a “hold” rating to a “buy” rating in a report on Monday, February 5th. Berenberg Bank started coverage on shares of Intersect ENT in a report on Friday, April 20th. They issued a “buy” rating for the company. Guggenheim reaffirmed a “buy” rating on shares of Intersect ENT in a report on Thursday, March 1st. Finally, Canaccord Genuity reaffirmed a “buy” rating on shares of Intersect ENT in a report on Monday, May 7th. Two analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. Intersect ENT presently has a consensus rating of “Buy” and an average target price of $38.50.
Shares of Intersect ENT opened at $38.70 on Friday, MarketBeat Ratings reports. The company has a market capitalization of $1.17 billion, a P/E ratio of -69.11 and a beta of 0.75. Intersect ENT has a fifty-two week low of $21.65 and a fifty-two week high of $42.25.
In other news, insider Lisa D. Earnhardt sold 15,000 shares of the business’s stock in a transaction on Monday, April 16th. The shares were sold at an average price of $39.59, for a total value of $593,850.00. Following the completion of the transaction, the insider now owns 499,683 shares of the company’s stock, valued at approximately $19,782,449.97. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Jeryl L. Hilleman sold 12,833 shares of the business’s stock in a transaction on Thursday, May 3rd. The shares were sold at an average price of $39.94, for a total transaction of $512,550.02. Following the completion of the transaction, the chief financial officer now directly owns 36,265 shares of the company’s stock, valued at approximately $1,448,424.10. The disclosure for this sale can be found here. Insiders have sold a total of 68,499 shares of company stock valued at $2,625,452 in the last ninety days. Company insiders own 5.90% of the company’s stock.
Hedge funds have recently made changes to their positions in the company. SG Americas Securities LLC bought a new stake in Intersect ENT in the 1st quarter valued at $132,000. Bank of Montreal Can bought a new stake in Intersect ENT in the 4th quarter valued at $135,000. UBS Group AG lifted its position in Intersect ENT by 81.1% in the 1st quarter. UBS Group AG now owns 4,679 shares of the medical equipment provider’s stock valued at $184,000 after acquiring an additional 2,096 shares in the last quarter. Aperio Group LLC bought a new stake in Intersect ENT in the 1st quarter valued at $213,000. Finally, Elkfork Partners LLC bought a new stake in Intersect ENT in the 4th quarter valued at $237,000. 83.66% of the stock is owned by institutional investors.
Intersect ENT Company Profile
Intersect ENT, Inc, a drug delivery company, researches and develops products for the treatment of patients with ear, nose and throat conditions in the United States. It offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.